X-Nico

4 unusual facts about Guidant


Drug-eluting stent

Guidant, which has the exclusive license to use everolimus in drug-eluting stents, is the manufacturer of both stents.

Guidant

On December 5th, 2005, Boston Scientific made a surprise unsolicited $24.6 billion bid to acquire Guidant, offering $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share.

Marion Greene

After earning her M.B.A. from the University of Texas in Texas, Greene moved to the Twin Cities, where she worked in marketing for Pillsbury and General Mills before shifting to the medical device industry, working for Guidant and St. Jude Medical.

Mir Imran

He received his B.S. in electrical engineering and his M.S. in biomedical engineering and attended three years of Medical School before deciding to leave and work on the first implantable cardioverter-defibrillator with Intec Systems, which was acquired by Eli Lilly, spun out to form Guidant, and acquired by Boston Scientific in 2006 for $27.5B


Juan Pablo Cappello

The more important cases he helped to represent include Bush v. Gore, and the merger between Guidant and Boston Scientific.

Termination fee

For instance, in 2005 Johnson & Johnson agreed to acquire Guidant, but Guidant later accepted a competing offer and was subject to a termination fee of $705 million.


see also